Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company’s lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité – Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom. As of November 20, 2024, Exscientia plc operates as a subsidiary of Recursion Pharmaceuticals, Inc..
AI Biotech Merge | Exscientia's merger with Recursion Pharma aims to create an AI-driven biotech powerhouse, potentially revolutionizing drug discovery and development processes |
Pipeline Progress | Key clinical programs, including CDK7 and MALT1 inhibitors, are advancing with potential data readouts that could significantly impact company valuation |
Financial Outlook | Extended cash runway into 2027 provides stability, but ongoing losses and negative EPS forecasts highlight challenges faced by clinical-stage biotech firms |
Market Dynamics | Analysts' price targets range from $5 to $10, reflecting mixed views on Exscientia's potential amid fierce competition and regulatory challenges in the biotech secto |